Command Palette

Search for a command to run...

Preprint WatchMildOctober 21st, 2026

Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis

Moser, B. A.; Madubata, C.; Chou, M.; Lotstein, M. L.; Zheng, Z.; Agashe, T.; Almonte-Loya, A.; Laflam, T. N.; Rynda, A.; Fox, J.; Turnier, J.; Gudjonsson, J.; Kahlenberg, J. M.; Fragiadakis, G. K.; Nagaraju, K.; Rosenblum, M. D.; Kim, S.; Gartner, Z.; Sirota, M.; Neely, J.

CD38 is an active regulator of type I interferon responses in juvenile dermatomyositis rather than a passive marker of disease activity.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

This preprint argues that CD38 is an active regulator of type I interferon responses in juvenile dermatomyositis rather than a passive marker of disease activity, reporting that CD38 expression tracks active disease, normalises in remission, and labels the cells carrying the strongest interferon signatures. The Claidex graph holds one CD38 failure, gen3014-hexabody-cd38-rrmm-portfolio-shutdown, a Phase 1/2 of the hexamerisation-enhanced CD38 antibody GEN3014 in relapsed or refractory multiple myeloma that the sponsor discontinued after a review of the data. That termination was a portfolio decision in an oncology indication and carries no efficacy or safety read on CD38 biology in autoimmune disease, which is why severity is mild. The useful inference runs the other way. A clinically validated CD38-depleting antibody class already exists, so the causal claim made here is directly testable in patients without new chemistry.

Abstract excerpt

Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is driven by an overactive type I interferon signaling pathway. CD38, a NAD+-consuming ectoenzyme with known roles in immune cell metabolism, is elevated in JDM, but whether CD38 marks disease activity or plays a causal role in pathogenesis remains to be determined. The authors show that CD38 identifies disease-relevant immune populations, rises with active disease, normalizes with clinical remission, labels the cells bearing the strongest interferon signatures, and localizes to sites of disease.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.